Seqens key facts
as of Oct 2026- Manufacturer of pharmaceutical ingredients and specialty ingredients based in Ecully, France.
- Seqens is valued at approximately $1.6B as of Oct 2026 (last reported valuation).
- It has raised $543.8M; the latest was PE Growth/Expansion ($570K) in Mar 2025.
- Notable investors include Bpifrance, Societe Generale Capital Partenaires, Caisse des Depots Group, Crescent Capital Group, Eximium — 8 tracked in total.
- Status: Privately Held (backing).
Seqens's last reported valuation, Nov 2022. Nothing priced has surfaced since.
- ·Watch Seqens: the Monday email on marks, rounds and moves
Seqens funding rounds
No funding rounds for Seqens are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Seqens valuation
Seqens's last reported valuation was $1.6 billion in Nov 2022. No priced round, secondary trade or fund mark has surfaced since.
Seqens investors
8 investors are on record for Seqens, including Bpifrance, Societe Generale Capital Partenaires, Caisse des Depots Group and Crescent Capital Group.
About Seqens
Manufacturer of pharmaceutical ingredients and specialty ingredients based in Ecully, France. The company specializes in aspirin, paracetamol, salicylic acid, para-aminophenol, soda ash, sodium bicarbonate, phenol, oxygenated solvents, ferric chloride and other active pharma ingredients, primarily serving demanding industries such as healthcare, electronics, cosmetics, food and household cleaners.
- Sector
- Healthcare
- HQ
- Ecully, France
- Founded
- 2003
- Employees
- 2,700
- Website
- seqens.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.